Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
CagriSema37 residues (approx.)KCNTATCATQRLANFLVHSSNNFGPILPPTNVGSNTYEach bubble = one amino acid. Size = residue mass. Color = chemical class.Uses closest standard amino acids for non-standard residues.Also known as: CagriSema, cagrilintide-semaglutide, NNC9204-1706
REDEFINE 1 enrolled 3,417 adults and recorded 22.7% mean body weight loss over 68 weeks. CagriSema is Novo Nordisk's fixed-dose combination of cagrilintide (a long-acting amylin analog) and semaglutide (a GLP-1 receptor agonist) in a single weekly pre-filled pen. It beat semaglutide alone by nearly seven percentage points. Fewer than two-thirds of trial participants reached the full 2.4/2.4 mg maintenance dose, though, and REDEFINE 4 (February 2026, n=809) showed tirzepatide producing 25.5% loss compared to CagriSema's 23.0%. The NDA was filed in December 2025. Adults with obesity seeking results beyond GLP-1 monotherapy are tracking the FDA decision expected around October 2026.
22.7% of body weight gone in 68 weeks. That number comes from REDEFINE 1 [1], a Phase 3 trial of 3,417 adults with obesity or overweight. CagriSema (cagrilintide 2.4 mg plus semaglutide 2.4 mg) is a fixed-dose combination in one pre-filled pen. Novo Nordisk developed it. Cagrilintide is a long-acting amylin analog. Semaglutide is the GLP-1 receptor agonist behind Ozempic and Wegovy. Each targets a separate appetite circuit in the brain; the combination produces additive suppression confirmed in head-to-head arms of the same trial. Roughly 40% of participants on the full dose lost 25% or more of their body weight. Another 23% crossed the 30% threshold. In adults with type 2 diabetes, REDEFINE 2 [2] recorded 15.7% weight loss, and 73.5% of participants reached HbA1c at or below 6.5%. Positioning got complicated in February 2026. REDEFINE 4 (n=809) tested CagriSema against tirzepatide 15 mg. CagriSema hit 23.0%; tirzepatide landed at 25.5%. The primary non-inferiority endpoint was missed. That head-to-head result shifted the conversation about where this drug fits. The NDA was filed in December 2025. No PDUFA date has been publicly announced; standard review timelines point toward an FDA decision around October 2026. Grey-market access means stacking separate research-grade cagrilintide and semaglutide vials, a fundamentally different product than the proprietary co-formulation tested in Phase 3.
Two appetite pathways, one injection. That is the core idea behind CagriSema. Cagrilintide is a synthetic analog of amylin, a 37-amino-acid hormone co-secreted with insulin from pancreatic beta cells. It activates amylin receptors (calcitonin receptor paired with receptor activity-modifying proteins, or RAMPs) in the area postrema and hypothalamus. Activation slows gastric emptying and sends early satiety signals that reduce meal size. A lipid side chain extends the half-life to approximately 184 hours. Semaglutide activates GLP-1 receptors in the hypothalamus and brainstem nucleus tractus solitarius. Downstream effects include glucose-dependent insulin secretion, glucagon suppression, and central appetite reduction through incretin signaling. Its half-life runs about 158 hours. These two receptor systems occupy different real estate in the brain. Amylin receptors signal primarily through the area postrema. GLP-1 receptors concentrate in the hypothalamus and nucleus tractus solitarius. REDEFINE 1 confirmed additive appetite suppression: 22.7% weight loss for the combination vs 16.1% for semaglutide alone and 11.5% for cagrilintide alone. Neither component matched the combination, confirming true pharmacological additivity. Both components also slow gastric emptying. That overlap explains why GI adverse events hit 80% of REDEFINE 1 participants, the highest rate of any GLP-1 class drug.
Phase 3 REDEFINE program confirms 22.7% body weight loss (efficacy estimand, REDEFINE 1) in obesity without T2D at 68 weeks: highest of any NDA-filed weekly injectable as of April 2026. REDEFINE 4 (Feb 2026) showed CagriSema at 23.0% weight loss failed non-inferiority vs tirzepatide at 25.5%. NDA filed December 2025; FDA decision estimated ~October 2026.
REDEFINE 1 (NEJM June 2025, PMID 40544433): n=3,417, 68-week Phase 3 RCT, CagriSema vs semaglutide alone vs cagrilintide alone vs placebo. REDEFINE 4 (Feb 2026, n=809): head-to-head vs tirzepatide 15 mg: CagriSema 23.0% vs tirzepatide 25.5%; primary endpoint (non-inferiority) not achieved.
Not yet FDA-approved (NDA under review). Failed non-inferiority vs tirzepatide in REDEFINE 4. DEXA sub-study (n=252) showed 33% of weight lost was lean soft-tissue mass. Fewer than 2/3 of REDEFINE 1 participants reached full 2.4/2.4 mg maintenance dose by week 68. CVOT (REDEFINE 3, n=~7,000) ongoing: no cardiovascular outcomes data yet. 80% GI adverse event rate is the highest of any GLP-1 class drug.
High interest driven by trial data. Actual grey-market access requires DIY stacking of separate research-grade cagrilintide + semaglutide. Users report strong appetite suppression but significant GI burden early in titration. REDEFINE 4 failure vs tirzepatide dampened enthusiasm in early 2026. Community consensus: do not initiate without prior GLP-1 experience.
Community follows REDEFINE titration schedule closely on dose escalation. Divergence: community uses separate research-grade cagrilintide + semaglutide (not the proprietary fixed-dose co-formulation validated in Phase 3). Some community protocols front-load cagrilintide titration faster than semaglutide. Both science and community agree the starting dose is 0.25 mg per component: community knows the correct initiation dose.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 0.25mg | Weekly |
| Moderate | 1.7mg | Weekly |
| Aggressive | 2.4mg | Weekly |
CagriSema comes as a pre-filled pen. No reconstitution, no BAC water, no vial math. Dial to the prescribed dose, inject, done. Store at 2 to 8 degrees Celsius; do not freeze. For the grey-market DIY route (separate cagrilintide plus semaglutide vials), the reconstitution math matters. A 5 mg cagrilintide vial with 2 mL BAC water gives 2.5 mg/mL. For the 0.25 mg starting dose, draw 0.1 mL (10 IU on an insulin syringe). A 10 mg vial with 2 mL gives 5 mg/mL; the same 0.25 mg dose is 0.05 mL (5 IU). Run semaglutide math based on your vial concentration. The 16-week titration is non-negotiable. Four weeks at each step: 0.25, 0.5, 1.0, 1.7, then 2.4 mg per component. Do not skip steps. Community users who rushed titration ended up with severe nausea and often quit entirely. If 1.7 mg is your ceiling, stay there; fewer than two-thirds of REDEFINE 1 participants made it to the full dose, and 1.7 mg still produces meaningful weight loss.
Based on 68-week REDEFINE Phase 3 trial design. Intended for long-term use. Weight regain expected upon discontinuation, consistent with GLP-1 agonist class. Titrate over 16 weeks before reaching maintenance dose.
CagriSema is intended for long-term continuous use, not cycled. REDEFINE 1 ran 68 weeks continuously; onWeeks: 68, offWeeks: 0 in peptides.ts is correct. Treatment breaks are indicated only for safety reasons (pancreatitis, gallbladder complications, thyroid monitoring) or if reaching goal weight with a supervised taper to lowest effective maintenance dose. Weight regain is documented upon discontinuation, consistent with the GLP-1 class: making cycling off counterproductive for obesity management.
Or use the universal Peptide Calculator for any peptide.
Expected: 22.7% mean body weight loss at 68 weeks (efficacy estimand); 20.4% treatment-policy estimand. ~40% achieve ≥25% loss; ~23% achieve ≥30% loss. Systolic BP reduction ~10.9 mmHg (AHA Hypertension 2025 sub-study). hsCRP reduction ~68.9%.
Monitor: Weight monthly; HbA1c and fasting glucose quarterly (pre-diabetic patients); lipid panel baseline and 6 months; BP monthly during titration, quarterly at maintenance; amylase/lipase if abdominal pain; DEXA at baseline and 6 months recommended to track lean mass.
Same day every week. Any time of day, with or without food.
For the pre-filled pen (commercial product, pending FDA approval): remove the cap, attach a pen needle (30 to 32 gauge, 4 to 8 mm), and dial to the prescribed dose. Clean the injection site with an alcohol swab. Inject subcutaneously into the abdomen (at least 2 inches from the navel), front of the thigh, or back of the upper arm. Hold for 10 seconds. Rotate sites weekly.
For DIY research-grade stacking: reconstitute cagrilintide and semaglutide in separate vials. A 5 mg cagrilintide vial plus 2 mL BAC water gives 2.5 mg/mL. Doses by titration step: 0.25 mg equals 10 IU (0.1 mL); 0.5 mg equals 20 IU (0.2 mL); 1.0 mg equals 40 IU (0.4 mL); 1.7 mg equals 68 IU (0.68 mL); 2.4 mg equals 96 IU (0.96 mL).
Draw each peptide into a separate insulin syringe (29 to 31 gauge). Do not combine them in one syringe. No validated stability data supports pre-blended mixtures outside Novo Nordisk's proprietary formulation.
Pinch a skin fold, insert at 90 degrees, inject slowly, hold for 5 to 10 seconds, withdraw.
Follow the 16-week titration: weeks 1 to 4 at 0.25/0.25 mg, weeks 5 to 8 at 0.5/0.5 mg, weeks 9 to 12 at 1.0/1.0 mg, weeks 13 to 16 at 1.7/1.7 mg, then 2.4/2.4 mg maintenance from week 17 onward.
Use within 28 days. Do not freeze.
GHRH analog: stimulates pulsatile GH release to preserve lean mass during aggressive caloric restriction from CagriSema. REDEFINE 1 DEXA sub-study showed 33% lean mass loss; community uses GH secretagogues to mitigate this.
100 mcg 2–3x daily, last injection before bed. Combine with Ipamorelin for GH pulse augmentation.
GHRP: combined with CJC-1295 for GH pulse augmentation with minimal cortisol/prolactin side effects. The dominant community lean-mass preservation stack for GLP-1/amylin protocols.
100 mcg 2–3x daily with CJC-1295. Before bed required; pre-workout optional.
GHRH analog with proven visceral fat reduction and GH secretagogue effects; alternative to CJC-1295 for muscle preservation during GLP-1 caloric restriction. Has actual clinical trial data for body composition.
2 mg nightly subcutaneous injection. Can substitute for or complement CJC-1295 stack.
Tissue repair and GI mucosal healing peptide. Community uses to mitigate GI side effects of CagriSema (nausea, mucosal irritation) and connective tissue stress during rapid weight loss.
250–500 mcg daily oral or subcutaneous; oral preferred for GI-specific benefit.
CagriSema already contains cagrilintide 2.4 mg at maintenance: additional cagrilintide creates amylin receptor over-stimulation and dramatically worsens GI adverse event risk.
Do not combineCagriSema already contains semaglutide 2.4 mg: do not add additional semaglutide. Redundant GLP-1 agonism with additive GI risk and no meaningful additional efficacy.
Do not combineOverlapping GLP-1 agonism (CagriSema contains semaglutide). Additive GI toxicity without additive weight loss benefit. REDEFINE 4 compared these head-to-head: they are alternatives, not complements.
Do not combineTriple receptor agonist with GLP-1 component: GLP-1 mechanism overlaps with semaglutide in CagriSema. Combined GI adverse event burden would be extreme. No evidence base for combination.
Do not combinePricing updated 2026-04-09
80% of REDEFINE 1 participants experienced gastrointestinal adverse events. That is the highest GI rate of any GLP-1 class drug in a Phase 3 trial. For comparison, semaglutide alone in STEP 1 hit roughly 44%. The additive amylin effect on gastric motility drives the difference. Nausea affected 55% of participants. Constipation hit 31%. Vomiting was reported in 26%. Diarrhea was also common. Most events graded mild to moderate and concentrated in the first 16 weeks during dose titration. They tend to diminish as the body adapts to dual receptor activation. But "mild nausea" five days a week still disrupts daily life, and an 80% rate means the clear majority of users will face some degree of GI disturbance. Constipation deserves separate attention because both components slow gut motility through independent mechanisms. Amylin delays gastric emptying from above; GLP-1 slows intestinal transit from below. The synergistic effect is predictable and was the most persistent GI complaint even after titration, based on community reports. Fiber, hydration, and osmotic laxatives (polyethylene glycol) are typically enough to manage it. Lean mass loss is a less visible but important concern. The REDEFINE 1 DEXA sub-study (n=252) found that 33% of total weight lost was lean soft-tissue mass. At 22.7% total body weight loss, that is a large absolute quantity of muscle and bone mineral content. Resistance training three to four times weekly, protein intake at or above 1.2 g/kg body weight, and GH secretagogue stacking (CJC-1295 no DAC plus Ipamorelin) are the standard community countermeasures. Fewer than two-thirds of trial participants reached the full 2.4/2.4 mg maintenance dose. GI tolerability was the barrier. Skipping titration steps makes outcomes worse. Community users who started at 0.5 mg (double the correct starting dose) reported universally more severe nausea lasting weeks longer than the standard protocol. Pancreatitis is a GLP-1 class risk. Persistent abdominal pain with nausea needs urgent evaluation with amylase and lipase testing. Do not attribute abdominal pain to "normal GI side effects" without ruling out pancreatitis. The medullary thyroid carcinoma (MTC) boxed warning applies through the semaglutide component, based on rodent thyroid C-cell tumor data. Anyone with a personal or family history of MTC or MEN2 should not use CagriSema. Baseline TSH testing is recommended with annual monitoring. Rapid weight loss increases cholelithiasis (gallstone) risk. An abdominal ultrasound at baseline and six months is worth considering for anyone losing more than 1% body weight per week. Discontinuation due to adverse events ran about 6% in REDEFINE 1. Injection site reactions can occur but are generally minor with the pen format. Pregnancy and breastfeeding are contraindicated. No reproductive safety data exists for the combination.
Verify CagriSema dosing and safety with a second opinion
CagriSema is not FDA-approved and not commercially available. All grey-market access requires DIY stacking of separate research-grade cagrilintide and semaglutide: which are not equivalent to the proprietary pH-adjusted co-formulation used in REDEFINE trials. Cagrilintide is a lipidated peptide (acyl chain modification); lipidated synthesis is significantly more complex and failure-prone than standard peptide synthesis. No compounding pharmacies can legally compound cagrilintide in the US.
| Test | When | Target |
|---|---|---|
| Body weight | Weekly during titration; monthly at maintenance | Gradual 0.5–1.5% loss per week during active loss phase |
| HbA1c | Baseline; every 3 months (especially T2D and pre-diabetic patients) | <5.7% (normal); <7.0% (T2D clinical goal) |
| Fasting glucose | Weekly for first 4 weeks; monthly thereafter (more frequently if on insulin or sulfonylurea) | 70–100 mg/dL (normal); 80–130 mg/dL (T2D pre-meal per ADA) |
| Lipid panel (fasting) | Baseline; 6 months | LDL <100 mg/dL; Triglycerides <150 mg/dL |
| Blood pressure | Monthly during titration; quarterly at maintenance | <130/80 mmHg |
| Amylase and Lipase | Baseline; immediately if abdominal pain develops | — |
| Liver enzymes (AST, ALT) | Baseline; annually | — |
| DEXA body composition | Baseline; 6 months (optional but strongly recommended) | Fat mass loss >70% of total weight lost |
| TSH (thyroid) | Baseline; annually or if symptoms develop | — |
| Abdominal ultrasound | Baseline; at 6 months if losing >1% BW/week | — |
Primary efficacy marker. Loss >1.5% BW/week increases gallbladder (cholelithiasis) and lean mass risk.
CagriSema improves glycemic control significantly; concurrent diabetes medications often require dose reduction to prevent hypoglycemia.
Hypoglycemia risk in T2D patients: CagriSema reduces caloric intake rapidly while improving insulin sensitivity.
CagriSema improves lipids; documents cardiometabolic benefit and guides statin management.
AHA Hypertension 2025 sub-study (PMID 41328546): CagriSema reduces systolic BP -10.9 mmHg vs -2.8 mmHg placebo. ~40% of patients on antihypertensives reduced or stopped medications. Monitor for over-correction.
Pancreatitis is a GLP-1 class risk; abdominal pain with nausea must be evaluated emergently.
Establishes reference; GLP-1 agonists improve MASLD; documents hepatic safety.
REDEFINE 1 DEXA sub-study (n=252) showed 33% of weight lost was lean soft-tissue mass: tracking allows timely intervention (protein, resistance training, GH secretagogues) before excessive lean mass loss.
GLP-1 class carries theoretical MTC risk (rodent data). CagriSema inherits this class warning from the semaglutide component.
Cholelithiasis (gallstones) risk increases with rapid weight loss. Baseline establishes gallbladder status; follow-up if rapid weight loss trajectory.
Initial titration phase. GI side effects (nausea, constipation) most common early. Mild appetite reduction may begin. Body adapts to dual amylin + GLP-1 activation.
Appetite suppression becomes more noticeable. Early weight loss of 2-5% expected. Nausea typically starts to subside as the dose stabilizes.
Continued titration with progressive appetite and hunger reduction. Steady weight loss accelerates. Blood glucose and insulin sensitivity improve in those with type 2 diabetes.
Full therapeutic dose. REDEFINE 1 showed 22.7% mean weight loss by week 68 (treatment-policy: 20.4%). About 40% of patients reached ≥25% loss and 23% reached ≥30%. GI side effects largely resolved.
Long-term maintenance at reduced body weight. Continued metabolic and cardiometabolic benefits expected while on therapy. Weight regain likely if treatment is stopped.
Weeks 1 through 4 (0.25 mg/0.25 mg): The first month is about GI adaptation, not weight loss. Both amylin and GLP-1 receptors engage immediately, slowing gut motility from injection one. Expect less than 1% body weight change. Nausea and constipation are at their worst during this window. Community reports split: some users tolerate the starting dose well, while others report significant nausea from the first shot. Users who started at 0.5 mg (skipping this step) reported universally worse outcomes. Appetite reduction is noticeable but subtle. Weeks 5 through 8 (0.5 mg/0.5 mg): Appetite suppression picks up. Early weight loss of 2 to 4% body weight is expected. Community users describe this phase as comparable to semaglutide 1.0 mg with an added fullness signal from the amylin component. "Food noise" begins fading. GI symptoms stabilize for most, though constipation often peaks during this window before improving. Fatigue is common. Weeks 9 through 16 (1.0 to 1.7 mg per component): The most dramatic phase. Hunger drops to near-absent levels. Portion sizes shrink substantially. Weight loss accelerates and blood glucose improves in those with type 2 diabetes. Most GI adaptation is complete by week 12. Some users report fatigue from rapid caloric reduction and become focused on protein intake. Hair thinning (telogen effluvium, consistent with rapid weight loss and not drug-specific) starts in a subset of users. Weeks 17 through 68 (2.4 mg/2.4 mg maintenance): Full therapeutic dose. REDEFINE 1 recorded 22.7% mean weight loss by week 68. Systolic blood pressure dropped 10.9 mmHg (AHA Hypertension 2025)[3]. hsCRP fell 68.9%. About 40% of participants reached 25% or greater weight loss. Plateaus are less common than on semaglutide alone, per community reports. The primary ongoing concerns are cost ($400 to $700 per month on the grey market), lean mass preservation, and gallbladder monitoring. REDEFINE 4 results in February 2026 prompted some community members to reconsider tirzepatide as an alternative. Post-discontinuation: Weight returns. No CagriSema-specific post-treatment data exists. By analogy with semaglutide cessation trials (STEP 1 extension), roughly two-thirds of lost weight comes back within a year of stopping. Appetite returns within one to two weeks of the last injection. Community consensus: long-term or indefinite use is required to hold results. Some users explore tapering to the lowest effective maintenance dose (1.0 or 1.7 mg per component) to reduce cost.
Minimal weight loss (<1%). Highest frequency of GI events (nausea, constipation, decreased appetite onset). Both amylin and GLP-1 receptors begin to engage; GI motility slowing begins immediately.
Variable GI tolerance: some users report significant nausea from the first injection; others tolerate well. Users who started at 0.5 mg (incorrect) universally report worse outcomes. Appetite reduction is noticeable but subtle at this dose.
Early weight loss 2–4% body weight. GI symptoms begin to attenuate as receptor adaptation occurs. Measurable satiety signal improvement.
"Food noise" reduction begins. Community describes this as comparable to semaglutide 1.0 mg with added amylin satiety effect (fullness signals appear faster at meals). GI symptoms improving but still present for most.
Weight loss accelerates; most GI adaptation complete by week 12. HbA1c improvements evident in T2D patients by week 9–12. Appetite suppression becomes pronounced.
Community describes this as the most dramatic phase: hunger near-absent, portion sizes reduce dramatically. Some report fatigue from rapid weight loss and elevated focus on protein intake. Hair thinning begins in some (telogen effluvium consistent with rapid weight loss, not drug-specific).
22.7% mean body weight loss by week 68 (efficacy estimand, REDEFINE 1). BP reduction -10.9 mmHg systolic (AHA Hypertension 2025, PMID 41328546). hsCRP reduction -68.9% (ObesityWeek 2025 post-hoc). ~40% achieve ≥25% weight loss.
Strong satisfaction at full maintenance. Plateaus less pronounced than reported on semaglutide alone. Cost is primary ongoing concern (~$400–700/month grey-market). REDEFINE 4 results (Feb 2026) led some community members to reconsider tirzepatide instead.
Weight regain expected upon discontinuation: no post-treatment extension data specific to CagriSema yet. By analogy with semaglutide cessation trials (STEP 1 extension): ~2/3 of lost weight regained within 1 year of stopping.
Community universally accepts long-term or indefinite use is required to maintain results. Some explore dose reduction to lowest effective dose at goal weight to manage cost. Appetite returns within 1–2 weeks of stopping.
Source: Phase 1b trial (Enebo et al., Lancet 2021, PMID 33894838): semaglutide t½ 145-165h, cagrilintide t½ 159-195h
Loading the interactive decay curve.
CagriSema is not FDA-approved. Novo Nordisk filed a New Drug Application in December 2025. Standard review takes 10 to 12 months, placing a potential decision around October 2026. No PDUFA date has been publicly announced. The commercial product (a pre-filled pen co-formulation) is not yet available for purchase. Current access requires sourcing separate research-grade cagrilintide and semaglutide from peptide vendors. These are sold as research chemicals and not approved for human use. The DIY stack is not equivalent to the proprietary formulation tested in Phase 3 trials. No compounding pharmacies can legally compound cagrilintide in the US. Cagrilintide is a lipidated peptide with complex synthesis. Third-party certificates of analysis (HPLC plus mass spectrometry) from independent labs are strongly recommended. Semaglutide is not on the WADA prohibited list. Amylin analogs are not currently prohibited. WADA status for the commercial CagriSema combination has not been adjudicated separately. This content is for informational and research purposes only. Consult a licensed healthcare provider before starting any peptide protocol.
Peptide Schedule Research TeamReviewed Apr 20266 Citations
